Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | MAOA | P21397 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CALML3 | P27482 | 1/20 | 0.41 |
| ▸ | SDHA | P31040 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 11/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18408804 | 1.00 | MAOB (0.52) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL20333329 | 0.96 | MAOB (0.56) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL20332950 | 0.91 | MAOB (0.57) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL20296188 | 0.89 | MAOB (0.44) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL20332998 | 0.89 | MAOB (0.59) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL24169695 | 0.88 | MAOA (0.54) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL20296344 | 0.88 | MAOA (0.54) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL18410610 | 0.88 | MAOA (0.54) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL18410462 | 0.87 | MAOB (0.54) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL20296275 | 0.87 | MAOB (0.54) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964949-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20200148651-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10550092-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964949-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THPO, TBCD, OXA1L | MAOB 1541/4885MAOA 2234/4885LMNA 3725/4885 |
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THPO, TBCD, OXA1L | MAOB 1541/4885MAOA 2234/4885LMNA 3725/4885 |
| US-20200148651-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THPO, TBCD, OXA1L | MAOB 1541/4885MAOA 2234/4885LMNA 3725/4885 |
| US-10550092-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THPO, TBCD, OXA1L | MAOB 1541/4885MAOA 2234/4885LMNA 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.